A single experience in the conduction of clinical trial during COronaVIrusDisease-2019 pandemic.
Zelmira BallatoreAmalia GoudasFrancesco BozziAlessandra LucarelliMichela BurattiniGiulia RicciFrancesco SavinoRossana BerardiPublished in: Exploration of targeted anti-tumor therapy (2023)
The growing number of remote Site Initiation Visit (SIV) and meetings over the last 3 years suggests the feasibility of the on-line processes. The significant reduction in protocol deviations during 2021 is probably due to an under check of data during a pandemic. But that is also a possible key indicator of the coping strategy made out by clinical oncology to guarantee the continuity of care in clinical trials and to offer new opportunities of cancer care in a bad scenario such as a pandemic one.